Glenmark nasal spray cuts down viral load of Covid by 94% in 24 hrs

Glenmark’s nitric oxide nasal spray (NONS), which it sells under the brand FabiSpray in India, reduces the viral load of Sars-CoV-2 in high-risk adult Covid-19 patients by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of phase 3 trial of the drug published in The Lancet Regional Health Southeast Asia journal.

Glenmark had conducted the study on 306 vaccinated and unvaccinated adults with symptomatic mild Covid-19 disease across 20 clinical trial sites in India. The trial evaluated a seven-day treatment of NONS, plus the standard of care versus placebo